<DOC>
	<DOC>NCT03027245</DOC>
	<brief_summary>Study E7389-M044-504 is an observational, post-authorization, single-arm, prospective, multicenter cohort study conducted to characterize and determine the incidence of eribulin-induced peripheral neuropathy (PN), and the frequency and time to resolution of eribulin-induced PN in participants treated with eribulin in a real-life setting for locally advanced or metastatic breast cancer following one or two prior chemotherapeutic regimens for advanced disease.</brief_summary>
	<brief_title>Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<criteria>Locally advanced or metastatic breast cancer eligible for treatment with eribulin according to Fachinformation (German equivalent of Summary of Product Characteristics) Maximum of two prior chemotherapeutic regimens for advanced disease Age â‰¥18 years at the time of Informed Consent Ability to understand and willingness to respond to questions related to their health Decision for the participant to start treatment with eribulin has been made prior to inclusion in this study. Signed written Informed Consent Previous treatment with eribulin in any line of treatment Contraindication according to the Fachinformation of eribulin Pregnancy or lactation Participation in an interventional clinical trial at the same time</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>locally advanced or metastatic breast cancer</keyword>
	<keyword>peripheral neuropathy</keyword>
	<keyword>chemotherapy-induced peripheral neuropathy</keyword>
	<keyword>eribulin</keyword>
</DOC>